About BioScience Managers
BioScience Managers is a venture capital firm founded in 2003. It is primarily based out of Melbourne, Australia. As of Dec 2020, BioScience Managers has invested in 32 companies. It primarily invests in Series A round in Australia based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Post IPO round of Cynata Overall, BioScience Managers portfolio has seen 16 IPOs and 7 acquisitions including key companies like Congenica, Saluda Medical and CalciMedica. A lot of funds co-invest with BioScience Managers, with names like Hunter Hall sharing a substantial percentage of its portfolio. BioScience Managers has team of 20 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Post IPO & 1 more
Portfolio IPOs
Portfolio Acquisitions
BioScience Managers' List of Top Investments
BioScience Managers has a portfolio of 32 companies. Their most notable investments are in Pharmamark and ADC Biotechnology.Their portfolio spans across Australia, United Kingdom, United States and 3 more locations. They have invested in Life Sciences, HealthTech, High Tech and 4 other sectors, across stages such as Series A, Post IPO and 1 more. Here is the list of top investments by BioScience Managers:1. Congenica
Provider of a platform for clinical genome analytics for treating patients with genetic diseases. The company has a platform for genome-based medicine that is capable of detecting complex mutations, filtering clinically relevant variants, and deep clinical phenotyping, combined with outcomes focussed organization of client data, secure storage, and intuitive functionality to integrate, interrogate and share client data.
Key facts about Congenica
- Founded Year: 2013
- Location: Cambridge (United Kingdom)
- Annual Revenue: £4.87M as on Dec 31, 2023
- Stage: Acquired
- Total Funding till date: $81.9M
- Employee Count: 79 as on Dec 31, 2020
- Investors: BioScience Managers, Tencent and 39 Others
- Latest Funding Round: Grant (prize money), Jun 17, 2021, $*****
- Highlight: Acquired
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment. It offers a system that measures and records neural activation characteristics. The system quantifies stimulation levels to a clinician-defined target, continuously comparing neural activation with the target level. It automatically adjusts stimulation current to ensure consistent neural activation. The company focuses on neuromodulation solutions for chronic pain. It utilizes Evoked Compound Action Potentials to advance neuromodulation therapy.
Key facts about Saluda Medical
- Founded Year: 2010
- Location: Bloomington (United States)
- Stage: Public
- Total Funding till date: $530M
- Employee Count: 485 as on Mar 31, 2026
- Investors: Fidelity Investments, Wellington and 9 Others
- Latest Funding Round: Series F, Oct 30, 2025, $*****
- Highlight: Public
3. CalciMedica
Developer of CRAC channel inhibitor drugs for inflammatory diseases. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.
Key facts about CalciMedica
- Founded Year: 2006
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $76.7M
- Employee Count: 18 as on Jan 20, 2026
- Investors: Bering Capital, BioScience Managers and 10 Others
- Latest Funding Round: Venture Debt, Apr 06, 2025, $*****
- Highlight: Public
Provider of AI-based platform for surgical simulation using VR and haptics. It claims that the proprietary haptics system allows sensing resistance, texture, substance, and pressure, enabling professionals to practice and refine their surgical skills. Its platform syncs with a stylus connected to a standard-issue mechanical arm. Its stylus features two buttons, one to inject the virtual drug and the other to withdraw the needle. It knows the ideal injection pattern for the drug and gives the surgeon a score based on how accurately they have administered it. It claims that the simulations are hardware agnostic and thereby compatible with multiple headsets such as HTC Vive, Oculus Rift, and Microsoft Hololens.
Key facts about Fundamental Surgery
- Founded Year: 2012
- Location: Boston (United States)
- Annual Revenue: £4.7M as on Dec 31, 2024
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $39.6M
- Employee Count: 77 as on Dec 31, 2024
- Investors: BioScience Managers, Mayo Clinic Business Accelerator and 13 Others
- Latest Funding Round: Series B, Oct 23, 2024, $*****
- Highlight: Editors' Pick
Avita Medical develops and distributes products in Regenerative and Respiratory Medicine. The company’s regenerative and tissue-engineered products provide solutions utilizing the patient’s own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects. The Regenerative group of products uses proprietary technology to create a Regenerative Epithelial Suspension RES™ – an autologous suspension comprised of the cells and wound healing factors necessary to regenerate natural healthy skin. The Regenerative group of products includes ReCell® for the treatment of burns and Maxillo-Facial procedures, ReCell® for plastics/aesthetics and ReCell® for the treatment of lower leg chronic wounds. Additionally, the company commercializes innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases. Key respiratory products include the Funhaler® incentive asthma spacer designed specifically for the pediatric market. The Breath-A-Tech™ range optimizes the delivery of aerosol medication in the management of Asthma and COPD
Key facts about Avita Medical
- Founded Year: 1992
- Location: Cambridge (United Kingdom)
- Annual Revenue: $63.9M as on Dec 31, 2024
- Stage: Public
- Employee Count: 108 as on Dec 31, 2021
- Investors: NorthStar Impact, BioScience Managers and 6 Others
- Latest Funding Round: Post IPO, Aug 14, 2025, $*****
- Highlight: Public
BioScience Managers' Year-on-Year Investment Trends
BioScience Managers has invested in 33 companies over the last 14 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Cynata.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 |
2020 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
BioScience Managers' Investments by Stage
BioScience Managers has made 5 investments in Series A stage with an average round size of $4.25M, 2 investments in Post IPO stage with an average round size of $9.26M and 1 investment in Series B stage with an average round size of $10M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Post IPO | 2 |
Series B | 1 |
Note: We have considered here, only first round of investments
BioScience Managers' Investments by Sector
BioScience Managers has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications and Vertical SaaS. Notably, it has invested in 26 Enterprise (B2B) companies, 25 Tech companies, 13 Software companies and at least 6 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
HealthTech | 4 |
Enterprise Applications | 3 |
Vertical SaaS | 1 |
Note: We have considered here, only first round of investments
BioScience Managers' Investments by Geography
BioScience Managers has made most investments in Australia (3), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
Australia | 3 |
United Kingdom | 2 |
Canada | 1 |
Ireland | 1 |
United States | 1 |
Note: We have considered here, only first round of investments
BioScience Managers' recent investments
BioScience Managers has not made any investment in 2026 so far.Here are the most recent investments by BioScience Managers:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 11, 2020 | Australia | Post IPO | 4573 | - | |
Aug 08, 2019 | Australia | Series A | 3603 | - | |
May 18, 2018 | Canada | Series A | 6886 | [+2] | |
Apr 24, 2018 | United Kingdom | Series A | 7210 | ||
Sep 11, 2017 | Australia | Series A | 7341 | - |
IPOs and Publicly Listed companies in BioScience Managers' Portfolio
16 of BioScience Managers' portfolio companies have become public. Saluda Medical got listed on the Australian Securities Exchange (ASX), in Dec 2025 at marketcap of $442M and GEN inCode got listed on the London Stock Exchange (LSE) at marketcap of $64M.Here are BioScience Managers' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 05, 2025 | Feb 20, 2012 | Series B | 8082 | |
Jul 22, 2021 | - | - | 8409 | |
Sep 25, 2020 | - | - | 6589 | |
Sep 04, 2017 | - | - | 8019 | |
Aug 26, 2015 | - | - | 1413 |
Acquired companies in BioScience Managers' Portfolio
7 companies from BioScience Managers' portfolio have been acquired. The most recent acquisition were PKG Health in Oct 2025 by Empatica.Here are BioScience Managers' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 06, 2025 | - | - | 1402 | |
Sep 02, 2025 | - | - | 2615 | |
Apr 07, 2021 | Apr 24, 2018 | Series A | 5581 | |
Apr 13, 2017 | Oct 28, 2013 | Series A | 1617 | |
Jun 27, 2016 | - | - | 7767 |
Team profile of BioScience Managers
BioScience Managers has a team of 20 members including 2 Partners, 1 Venture Partner and 2 Principals located in Australia and United States. BioScience Managers' team does not sit on the board of any company as of now.Here is a list of top team members in BioScience Managers:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Perth | - | ||
Partner | - | - | ||
Venture Partner | Melbourne | - | ||
Principal | Melbourne | - | - | |
Principal | Princeton | - | - |
Co-investors of BioScience Managers
Over the past 14 years, 39 investors have co-invested in BioScience Managers's portfolio companies. This includes funds and angels.
- Invested before BioScience Managers: Defense.gov, NHMRC and 12 others have invested in rounds before BioScience Managers. There is 1 company where Defense.gov has invested before BioScience Managers and 1 company where NHMRC has invested before BioScience Managers.
- Top Co-investors of BioScience Managers: 7 investors entered a company along with BioScience Managers. These include investors like Hunter Hall (1 company).
- Invested after BioScience Managers: A total of 18 investors have invested in BioScience Managers's portfolio after their investments. Top Investors include Medtronic (1 company), Boston Scientific (1 company) and Redmile Group (1 company).
Recent News related to BioScience Managers
•
•
Cynata raises $15 million to fast-track stem cell therapies | The West AustralianThe West Australian•Dec 14, 2020•Cynata, BioScience Managers
•
•
•
Vancouver’s Canary Medical raises $10M in VC fundingFundingportal•May 23, 2018•Canary Medical, BioScience Managers, Quark Venture, GF Securities and 1 other
•
Bioscience Managers' Invests in Canary Medical's Proprietary 'Smart' Implant TechnologyPR Newswire•May 18, 2018•Canary Medical, BioScience Managers, Quark Venture, GF Securities and 1 other
•
Downing FOUR VCT invests £1.14 million in ADC Biotechnology LtdBusiness Wire•Apr 24, 2018•Downing, ADC Biotechnology, BioScience Managers
•
•
•
